PCSK9 inhibitors: what we know, what we should have understood, and what is to come-Reference-Cited by-同舟云学术

PCSK9 inhibitors: what we know, what we should have understood, and what is to come

Published:2019-07-23 Issue: Volume: Page:
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Sabatine Marc S¹^ORCID

Affiliation:

1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/advance-article-pdf/doi/10.1093/eurheartj/ehz514/28981963/ehz514.pdf

Reference11 articles.

1. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

2. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018

3. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials;Guedeney;Eur Heart J,2019

4. Interpretation of the evidence for the efficacy and safety of statin therapy;Collins;Lancet,2016

5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S);Lancet,1994

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition;Clinical Lipidology;2024

2. Induced alternative splicing an opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations;Scientific Reports;2023-11-13

3. Induced alternative splicing: opportunity to study PCSK9 protein isoforms at physiologically relevant concentrations;2023-06-30

4. PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid–Based Therapy Era;Current Atherosclerosis Reports;2022-07-28

5. The year in cardiovascular medicine 2021: dyslipidaemia;European Heart Journal;2022-01-03